MEASURE APPLICATIONS PARTNERSHIP

MAP 2017 Considerations for Implementing Measures in Federal Programs: Hospitals

FINAL REPORT FEBRUARY 15, 2017



This report is funded by the Department of Health and Human Services under contract HHSM-500-2012-00009I, Task Order HHSM-500-T0018.

# CONTENTS

| GUIDANCE ON CROSS-CUTTING ISSUES   | 2  |
|--|----|
| Summary  | 2  |
| OVERARCHING THEMES   | 3  |
| Move to High-Value Measures  | 3  |
| Reducing Measurement Burden  | 4  |
| CONSIDERATIONS FOR SPECIFIC PROGRAMS   | 5  |
| End-Stage Renal Disease Quality Incentive Program (ESRD QIP)   | 5  |
| Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting (PCHQR)  | 5  |
| Ambulatory Surgical Center Quality Reporting (ASCQR)   | 6  |
| Inpatient Psychiatric Facility Quality Reporting (IPFQR)   | 7  |
| Hospital Outpatient Quality Reporting (OQR)  | 8  |
| Inpatient Quality Reporting Program (IQR)/Medicare and Medicaid EHR Incentive Program for Hospitals and Critical Access Hospitals (Meaningful Use) | 9  |
| Hospital Value-Based Purchasing (VBP)  | 11 |
| Hospital Readmissions Reduction Program (HRRP)   | 11 |
| Hospital-Acquired Condition Reduction Program (HACRP)  | 11 |
| APPENDIX A: Program Summaries  | 12 |
| APPENDIX B: MAP Hospital Workgroup Roster and NQF Staff  | 19 |
| APPENDIX C: MAP Comments on Final Measures   | 20 |

# GUIDANCE ON CROSS-CUTTING ISSUES

## Summary

- MAP recognized a need for measures across programs that evaluate the appropriate use of health interventions and testing, including pre-operative testing.
- Effective care transitions are a pivotal lever for improving healthcare quality and are essential to appropriate follow-up care after hospitalization.
- MAP underscored the importance of patient-reported outcomes (PROs), and identified the need for measures based on patient-reported outcomes
- Measure selection should weigh data collection and reporting burden against potential to improve quality of care and patient outcomes. MAP emphasized that providers may have limited resources for measurement and that the addition of new measures to the programs should be balanced with the removal of measures that may no longer be needed.

The Measure Applications Partnership (MAP) Hospital Workgroup reviewed measures under consideration for seven hospital and settingspecific programs:

- End-Stage Renal Disease Quality Incentive Program (ESRD QIP)
- Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting (PCHQR)
- Ambulatory Surgical Center Quality Reporting (ASCQR)
- Inpatient Psychiatric Facility Quality Reporting (IPFQR)
- Hospital Outpatient Quality Reporting (OQR)
- Hospital Inpatient Quality Reporting (IQR) and Medicare and Medicaid EHR Incentive Program for Hospitals and Critical Access Hospitals (CAHs) (Meaningful Use)

• Hospital Value-Based Purchasing (VBP)

In addition, MAP provided feedback on the current measure sets for these programs, as well as the two hospital-specific programs listed below:

- Hospital-Acquired Condition Reduction Program (HACRP)
- Hospital Readmissions Reduction Program (HRRP)

MAP's pre-rulemaking recommendations for a measure in these programs reflect the MAP Measure Selection Criteria (MSC) and how well the measures address the goals of the program. The MSC are designed to highlight characteristics of an ideal measure set. The MSC are intended to complement program-specific statutory and regulatory requirements. The MSC focus on selecting high-quality measures that optimally address the National Quality Strategy's (NQS) three aims, fill critical measure gaps, and increase alignment among programs. The selection criteria seek measures that are NQF-endorsed whenever possible, address a performance gap, diversify the mix of measures types, relate to person- and family-centered care and services, relate to disparities and cultural competency, and promote parsimony and alignment among public and private quality programs.

# OVERARCHING THEMES

### Move to High-Value Measures

MAP noted the need for measures that address high priority areas. The group pointed out several key areas where future measure development is needed including appropriate use, care transitions, and patient-reported outcomes.

MAP recognized a need for measures across programs that evaluate the appropriate use of health interventions and testing, including preoperative testing. MAP recognized the need for measures to address both overuse of testing, as well as to monitor the appropriate use of testing. This theme was recognized as a priority because of its impact on efficiency, outcomes, and cost and resource use. MAP noted that patients often receive unnecessary incremental tests and that measures related to appropriate testing are also pivotal to improving care coordination. MAP observed an existing measure in the Hospital Outpatient Program, NQF #0669, which evaluates cardiac imaging for pre-operative risk assessment for noncardiac low-risk patients and suggested that similar measures might be considered for other programs that cover surgery.

In addition to testing, MAP stressed the importance of appropriate prescribing practices, in particular, as they relate to pain management and opioid prescription. MAP noted the need for measures that assess opioid follow-up, prescription, and appropriate prescribing. Finally, MAP identified imaging as an area where measurement could also be used to encourage appropriate use.

MAP also recognized the need for additional measures assessing care transitions and measuring coordination between hospitals and other settings. MAP discussed the importance of effective care transitions across the care continuum and the importance of ensuring access to appropriate follow-up care after hospitalizations. For example, MAP suggested possible measures related to primary care appointments following emergency hospitalizations for psychiatric conditions or measures related to the quality of the care environment to which patients are discharged after hospitalization.

MAP emphasized the need for measures based on patient-reported outcomes (PRO-PMs). MAP members noted that these measures could provide value particularly in the Inpatient Quality Reporting (IQR) program and the Hospital Value-Based Purchasing Program. MAP identified several areas where new measures could be used to help providers support patients/consumers in making decisions about their care. MAP also discussed the need for new approaches to capturing patientreported outcomes and developing those into performance measures and measures to help patients/consumers better understand their care and their own health.

The MAP 2016 In-Person Meeting included an overview and discussion of the Patient-Reported **Outcomes Measurement Information System** (PROMIS). MAP supported use of PRO-PMs in hospital programs, emphasizing the need to measure and improve the outcomes that matter most to patients. However, MAP did have concern as to how the tool could be feasibly used in accountability metrics. First, MAP members raised concerns about the potential burden of administering PRO instruments for both the patient and the provider. MAP members also noted challenges in standardizing self-reported outcomes across populations and cautioned that PRO-PMs should be appropriately risk-adjusted. MAP members raised questions about whether PRO-PMs would be based on changes in score and noted that it may be more appropriate to consider the changes within a facility rather than to compare to national averages. MAP also recognized the potential to use measures based on PROMIS to assess population health.

### **Reducing Measurement Burden**

When considering the addition of new measures, MAP emphasized the need for measures that will drive improvement and address unwarranted variation among providers. MAP recognized the importance of balancing the effort required for data collection and reporting with the potential a measure has to improve quality of care and patient outcomes. As noted above, the group said that special consideration should be given when a measure may put more burden on the patient to complete instruments. MAP reiterated that providers may have limited resources for measurement and that the addition of new measures to the programs should be balanced with the removal of measures that may no longer be needed. The group recommended removal of measures that are topped out, have unintended consequences, have lost NQF endorsement, or are no longer aligned with the current evidence or the program's goals. . However, MAP recognized that in order for CMS to act on these recommendations, it will likely need to engage in rulemaking as well as consider other

programmatic needs not taken into account by the MAP process. Details on MAP's recommendations on existing measures can be found in Appendix C.

MAP looked to electronic clinical quality measures (eCQMs) as a means to reduce data collection and reporting burden. MAP discussed several measures under consideration (MUCs) that would be an eCQM option for an existing chart-abstracted measure in the program set. MAP members supported the inclusion of the eCQMs because they reduced hospital burden in reporting the measures, but noted that several of the chart-abstracted measures were topped out. For example, there was discussion about Influenza Immunization (IMM-2) (MUC16-053), which is an eCQM similar to the chart-abstracted version, MUC16-055. Because of uniformly high performance across providers, this measure would not meet the NQF criteria for endorsement. However, MAP noted that if topped out measures are maintained in hospital programs, use of eCQMs for surveillance could reduce the burden of data collection.

# CONSIDERATIONS FOR SPECIFIC PROGRAMS

### End-Stage Renal Disease Quality Incentive Program (ESRD QIP)

The End-Stage Renal Disease Quality Incentive Program (ESRD QIP) is a pay-for-performance and public reporting program established to promote high-quality services in outpatient dialysis facilities treating patients with ESRD.

In its 2016-2017 pre-rulemaking deliberations, MAP reviewed three measures under consideration for the ESRD QIP program. MAP supported two measures intended to replace the current vascular access measures in the ESRD QIP program.

MAP recommended that one measure. Standardized Transfusion Ratio for Dialysis Facilities (MUC16-305), be refined and resubmitted prior to rulemaking. MAP noted the importance of this measure, recognizing the impact that anemia can have on a patient's quality of life and the potential consequences of a blood transfusion. However, some MAP members raised concerns that the dialysis facility may not have control over decisions about administering blood transfusions as patients may receive the transfusion in other care settings. MAP also discussed the variability in blood transfusion coding practices that could inadvertently affect a dialysis facility's performance on this measure. Overall, MAP stressed the importance of managing anemia and avoiding unnecessary blood transfusions in patients with ESRD and encouraged better care coordination between dialysis facilities and hospitals.

MAP reviewed the current measure set and noted the need for a comprehensive measure set that looks at both treatment and outcomes that would drive quality and safety for those with ESRD. MAP identified several gap areas including pediatrics and gaps relating to management of comorbid conditions, such as congestive heart failure, diabetes, and hypertension. There was a strong interest in patient-reported outcomes (PROs) for the dialysis population. A dialysis provider raised a concern regarding the possibility of surveillance bias for the blood stream infection measure. MAP recommended that non-endorsed measures used in the ESRD program be submitted for endorsement review (e.g., anemia and mineral reporting measures). Overall, MAP identified four out of the 18 current measures that could be removed from the program to reduce burden and provide opportunities to include higher-value measures. MAP also suggested that the current bloodstream infection measure (NQF #1460) could be modified to include thresholds for testing to allow for accurate comparisons between facilities and to ensure facilities are performing blood cultures appropriately. Details on MAP's comments on the current measures can be found in Appendix C.

Commenters agreed with the MAP recommendations overall, though commenters did have suggestions for improvements for specific measures, such adjustments to the specifications.

# Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting (PCHQR)

The Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting (PCHQR) program is a voluntary quality reporting and public reporting program. The program's goal is to provide information about the quality of care that is provided in the 11 cancer hospitals that are exempt from the Medicare Inpatient Prospective Payment System (IPPS).

In its 2016-2017 pre-rulemaking deliberations, MAP reviewed five measures for the PCHQR program. MAP supported four measures related to endof-life care. MAP has stressed the importance of end-of-life care as an area of cancer care needing improvement. MAP noted that the measures under consideration could help encourage the use of hospice care and could help avoid aggressive treatment in the last days of life. MAP noted that unnecessary treatment at the end of life has been found to have a negative impact on a person's quality of life and that these measures could help improve patient and caregiver experience.

MAP did not support one measure, PRO Utilization in Non-Metastatic Prostate Cancer Patients (MUC16-393), because it is a structural measure related to the measurement of PRO utilization rather than a patient-reported outcome measure. MAP noted that patients value the results of PROs; however, the value of this structural measure to patients/consumers was not clear.

Public comments differed regarding MUC16-393, as many commenters noted the increasing importance of patient-reported outcomes to CMS and to value-based care. Commenters generally agreed with the MAP recommendations regarding the end-of-life measures.

MAP reviewed the current measure set and recommended that three treatment-specific measures related to breast cancer, prostate cancer, and colon cancer be removed from the program in the future. MAP discussed the need for measures (including PRO-PMs) that could be used for patients with different types of cancer. Other gap recommendations from MAP included measures of global harm in inpatient settings and understanding of informed consent from a patient perspective. There was also a recommendation to consider which cancer measures should be routinely stratified to assess disparities. MAP also suggested increased alignment between the IQR and PCHQR programs, as the majority of cancer care does not occur in specialty cancer hospitals. MAP identified four out of the 17 current measures that could be removed from the program to reduce measurement burden. MAP also recommended that the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy

be revised as suggested by the NQF Cancer Standing Committee and resubmitted for NQF endorsement. Additional details on MAP's recommendations on current measures can be found in Appendix C.

# Ambulatory Surgical Center Quality Reporting (ASCQR)

The Ambulatory Surgical Center Quality Reporting (ASCQR) program is a pay-for performance and public reporting program. Ambulatory Surgical Centers (ACSs) that do not participate or fail to meet program requirements, receive a 2 percent reduction in annual payment update. The goals for the ASCQR program include: (1) promoting higherquality, more efficient healthcare for Medicare beneficiaries through measurement, and (2) providing consumers with quality information that will allow them compare the quality of care given at ASCs and help them make informed decisions about where they receive care.

In its 2016-2017 pre-rulemaking deliberations, MAP reviewed three measures under consideration for the ASCQR program. MAP conditionally supported MUC16-155 Ambulatory Breast Procedure Surgical Site Infection (SSI) Outcome Measure pending NQF endorsement and additional testing and monitoring before use in a value-based purchasing (VBP) program.

MAP recommended that two measures related to hospital visits after orthopedic and urological procedures be refined and resubmitted prior to rulemaking because they are still undergoing field testing and should be submitted to NQF for endorsement review.

MAP reviewed the measures currently included in the ASCQR program and noted that only six out of the 15 measures in the measure set are currently NQF-endorsed. MAP recommended the future removal of measures are not NQF-endorsed. MAP identified two out of the 15 measures that could potentially be removed. The program includes measures that have been previously endorsed but not submitted for maintenance review. An ASC measure developer commented that resource availability may be a limiting factor for submission and maintenance of measures. Public comments supported MAP's recommendations; however, a commenter noted that NQF endorsement is not required by the Social Security Act for measures adopted for the ASCQR Program.

MAP identified a significant number of measure gaps in the ASCQR program. MAP noted the need for measures addressing surgical quality regardless of where it is done, including site infections and complications, and measures of patient and family engagement. MAP highlighted the need for measures of efficiency, noting the need for appropriate pre-operative testing.

## Inpatient Psychiatric Facility Quality Reporting (IPFQR)

The Inpatient Psychiatric Facility Quality Reporting (IPFQR) program is a pay-for-reporting and public reporting program that requires inpatient psychiatric facilities (IPFs) to submit data on all required measures, to avoid receiving a 2 percent reduction in annual payment update. The IPFQR program goals are to provide consumers with quality of care information that will enable them to make more informed decisions regarding healthcare options, and encourage hospitals and clinicians to improve the quality of inpatient psychiatric care by ensuring that providers are both aware of and reporting on best practices.

In its 2016-2017 pre-rulemaking deliberations, MAP reviewed three measures for the IPFQR program. MAP recommended that all three measures, Medication Continuation following Inpatient Psychiatric Discharge (MUC16-048), Medication Reconciliation at Admission (MUC16-049), and Identification of Opioid Use Disorder (MUC16-428) be refined and resubmitted prior to rulemaking. MAP noted that the measures are currently undergoing testing and the results should demonstrate reliability and validity at the facility level in the hospital setting before implementation in an accountability program. In addition, regarding measure MUC16-O48, MAP discussed details in the measure specifications that need additional clarification such as (1) the definition of medication dispensation (2) how does the facility know the medication was dispensed? and (3) Medicare Part D is optional: how does this affect the measure? Regarding MUC16-O49, MAP had a lengthy discussion about the intent of the measure (i.e., timeliness versus accuracy of medication reconciliation) and chart abstraction burden. Finally, MAP also recommended that all three of the measures be submitted to NQF for endorsement review.

The majority of commenters supported MAP's recommendations. Commenters noted that measures (such as MUC16-428) may lead to over testing. There were also general comments regarding the MAP-identified gap area of access—where commenters were concerned that hospitals have limited control over this domain.

When reviewing the current measure set, MAP recommended that measures that have never been reviewed by NQF be submitted for endorsement review. MAP also noted the high number of alcohol and tobacco measures included in the program, and suggested that, while such measures are important, they should not be the highest priority indicators for quality treatment in psychiatric hospitals. Overall, MAP identified seven of the 20 current measures that could potentially be considered for removal from the program.

MAP identified areas for further development including medical comorbidities, emergency department patients not admitted to the hospital, discharge planning, and readmissions. Another gap area related to access to inpatient psychiatric services, especially in rural areas. MAP also suggested aligning the measures in the IPFQR program with measures in the IQR program when possible.

# Hospital Outpatient Quality Reporting (OQR)

The Hospital Outpatient Quality Reporting Program (OQR) is a pay-for-reporting and public reporting program. The goals of the program are to establish a system for collecting and providing quality data to hospitals providing outpatient services and provide consumers with quality-ofcare information to make more informed decisions about their healthcare options.

In the 2016-2017 pre-rulemaking deliberations, MAP reviewed three measures under consideration for the OQR program. MAP conditionally supported Median Time from ED Arrival to ED Departure for Discharged ED Patients (MUC16-055) for rulemaking. The conditions for support included that (1) the testing data demonstrate that this eCQM more accurately determines patient arrival and discharge times compared to the chartabstracted version of the measure (NQF #0496) currently in the HOQR and HIQR programs and (2) this eCQM is submitted to NQF for endorsement review. MAP members did express concern that without the right safeguards, implementation of this measure might lead to unintended negative consequences—such as patients being moved to observation, admitting patients without proper cause, and/or discharging patients unsafely.

The measure, Time to Pain Management for Long Bone Fracture (MUC16-056), was not supported by MAP because NQF endorsement was removed in 2014. The NQF Musculoskeletal Steering Committee noted that the evidence supporting this measure did not sufficiently link the process of measuring and reporting the time gap between arrival and administration of pain medication for long bone fractures to improved clinical outcomes. The Musculoskeletal Steering Committee agreed that less time to administration is likely better, but the evidence was also lacking to support a particular timeframe for treating pain in long bone fractures. In addition, MAP noted that the patient population and types of conditions may affect the performance of this measure because ED

discharge may be delayed intentionally for patient safety or other patient-specific reasons. MAP also acknowledged the potential for unintended consequences such as inappropriate and/or unsafe discharges to the community or patients moved to observation status.

A measure for evaluating Safe Use of Opioids, Concurrent Prescribing (MUC16-167), was given a recommendation of revise and resubmit due to the importance of the topic and the need for measures to address the ongoing opioid crisis. MAP noted that the specifications of the measure should be revised as there are times when concurrent prescriptions of opioids and benzodiazepines are appropriate. MAP was concerned that patients may unintentionally suffer withdrawal symptoms if previously prescribed opioids and/or benzodiazepines are reduced and/or stopped prior to discharge. Public comments varied regarding the discussion of MUC16-167, both supporting MAP's recommendation and suggesting that the measure be refined and resubmitted prior to rulemaking. Regarding MUC16-055, commenters noted that making it an eCQM would not fix the inherent problems with the measure.

When providing feedback on the current measure set, MAP recommended the future removal of measures that failed NQF endorsement review. Additionally, MAP members suggested the removal of the measure 0496 (Chart Abstracted Median Time from ED Arrival to ED Departure for Discharged ED Patients) as it is burdensome to collect. MAP noted that the current Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure should be modified as suggested by the NQF Cancer Standing Committee and resubmitted for endorsement review. Overall, MAP noted that 13 out of the 29 measures currently in the program (52 percent) could potentially be removed. Additional details on MAP's recommendations on current measures can be found in Appendix C.

MAP suggested that the measure set would be improved by adding measures that allow consumers and purchasers to make informed choices when choosing outpatient facilities. For example, the set could include measures that incentivize facility use of evidencebased practices. MAP also noted a need for a greater emphasis on communication and care coordination. As an example, MAP noted the importance of appropriate follow-up for patients discharged from the emergency department following a drug overdose. Finally, the group suggested the addition of measures around falls and accurate diagnosis.

# Inpatient Quality Reporting Program (IQR)/Medicare and Medicaid EHR Incentive Program for Hospitals and Critical Access Hospitals (Meaningful Use)

The Hospital Inpatient Quality Reporting Program (IQR) is a pay-for-reporting and public reporting program that requires hospitals paid under the Inpatient Prospective Payment System (IPPS) to report on process, structure, outcomes, patient perspectives on care, efficiency, and costs of care measures. The program has two goals: (1) to provide an incentive for hospitals to report quality information about their services, and (2) to provide consumers information about hospital quality so they can make informed choices about their care. Many measures in this program overlap with the Medicare and Medicaid EHR Incentive Program for Eligible Hospitals and Critical Access Hospitals (CAHs), which provides incentives eligible hospitals and CAHs that do not successfully demonstrate meaningful use by reducing Medicare payments.

MAP reviewed 15 measures for rulemaking for the IQR and/or Meaningful Use programs. MAP supported one measure, MUC16-179 Alcohol Use Screening, because it encourages hospitals to screen patients for alcohol use and can prevent alcohol withdrawal syndrome, which can be life-threatening. However, MAP emphasized that it did not support alcohol screening in order to identify brief interventions. MAP did not support the measures related to brief alcohol intervention and treatment prescription/referral provided at discharge because no evidence was provided demonstrating the impact of these processes on alcohol use. Similarly, MAP did not support the MUC16-068 Patient Panel Smoking Prevalence, because the evidence provided does not demonstrate that implementing this measure leads to a decrease in smoking prevalence. MAP also discussed several concerns regarding this measure including the impact of sociodemographic (SDS) factors, geographic region, attribution, and other factors beyond the hospital's control.

MAP recommended that the communication about pain composite measure (HP1, HP2, and HP3) be revised and resubmitted prior to rulemaking because the measure has only undergone field testing and results have not been published. MAP noted that measure is intended to replace the Pain Management composite measure in the HCAHPS Survey. MAP emphasized the need to include nonpharmacological options used to treat pain. MAP recommended that the testing results demonstrate reliability and validity for the Inpatient Quality Reporting (IQR) program. MAP also recommended that the measure be submitted to NQF for endorsement review.

MAP discussed the inclusion of four separate malnutrition measures under consideration for the IQR and EHR Incentive programs. MAP engaged in a lengthy discussion about the concerns identified by the Health and Well-Being Standing Committee currently reviewing the measures—and ultimately recommended that three of the measures be refined and resubmitted prior to rulemaking, and did not support the remaining measure. MAP concluded that completing a malnutrition assessment provided the most potential value to the measure set and quality of care. MAP encouraged the measure developer to test the individual malnutrition measures as a composite in an effort to balance the number of measures in the IQR program yet fill the gap on malnutrition.

MAP supported Influenza Immunization (IMM-2) (MUC16-053) for rulemaking with the condition that this eCQM serve as an option for facilities to report influenza vaccination rates to CMS. The current chart-abstracted version of this measure (NQF #1659) was recently recommended for Inactive Endorsement with Reserve Status by NQF's Health and Well-Being Standing Committee due to its high levels of performance and limited opportunity for further improvement. MAP acknowledged this eCQM's limited ability to improve quality due to the high levels of performance on the chart-abstracted version of this measure (NQF #1659), but highlighted potential for in data collection burden by eCQMs. MAP considered Measure of Quality of Informed Consent Documents for Hospital-Performed, Elective Procedures (MUC16-262), but did not support the measure for rulemaking because it captures the quality of informed consent documents rather than the quality of communication between patients and their providers. MAP acknowledged the importance of guality informed consent and recommended that future measures on informed consent be patient-centered.

When reviewing the current measure set for IQR, MAP highlighted the need for alignment among hospital programs. In particular, MAP members noted the passage of the 21st Century Cures Act and its provisions requiring considerations for the proportion of fully dually eligible patients served by a facility in the HRRP. MAP recommended that CMS explore ways to align the readmissions measures used for both IQR and HRRP and that CMS consider the recommendations of the Assistant Secretary for Planning and Evaluation (ASPE) in the *Report to Congress: Social Risk Factors and Performance Under Medicare's Value-Based Purchasing Programs* as required by the IMPACT Act of 2014. MAP recognized the burden created by the large number of measures required by the IQR program and recommended that CMS remove measures that are no longer driving improvements in patient care. MAP recommended the removal of measures that did not pass NQF endorsement initially or have lost NQF endorsement. MAP also recommended that measures in use in the program that have never been reviewed for NQF endorsement be submitted for review. MAP also recommended that CMS examine measures where performance is high and there is limited variation among providers to ensure there is still value in keeping these measures in the IQR set. Overall, MAP recommended the removal of six out of the 62 current measures that were not previously finalized for removal. Additional details on MAP's recommendations on current measures can be found in Appendix C.

Additionally, MAP recommended that measures in the IQR set that have not been reviewed by NQF be submitted for endorsement review. In particular, the MAP expressed concerns about the episode-based payment measures that have been added to IQR for FY 2019 and recommended that the measures be submitted for review by the NQF Cost and Resource Use Standing Committee.

Finally, MAP stressed the need for measures that matter most to patients. In particular, the group noted the need for more patient-reported outcomes and measures related to dementia in the IQR set. MAP suggested that the measure sets might consider more nuanced outcomes, providing insight on quality beyond mortality measures.

NQF received over 50 comments regarding IQR measures. The majority of commenters agreed with MAP recommendations. Commenters that disagreed with MAP's recommendations primarily commented on the malnutrition measures as well as MUC16-262 Measure of Quality of Informed Consent Documents for Hospital-Performed, Elective Procedures.

# Hospital Value-Based Purchasing (VBP)

The Hospital Value-Based Purchasing (VBP) program is a pay-for-reporting program. A portion of hospital reimbursement is withheld and used to fund a pool of incentive payments that hospitals can earn back over time. The goals of this program are to improve quality by realigning financial incentives and to provide incentive payments to providers that meet or exceed performance standards.

MAP did not support Communication about Pain During the Hospital Stay (MUC16-263) (HP1, HP2, and HP3) for rulemaking because it did not meet the program requirements for the HVBP program. The composite measure must be in IQR and publicly reported for at least one year before it may be considered for potential adoption in the HVBP program. Commenters agreed with the MAP recommendation and agreed that there was need for further debate and revision of this measure.

When reviewing the current measure set for VBP, the group made three recommendations. First MAP again recommended that CMS consider ASPE's recommendations for ways to mitigate the effect of the VBP program on safety net hospitals. Secondly, MAP members expressed concern with the reliability, actionability, and usability of Patient Safety Indicator (PSI) 90 Composite and recommended that CMS strive to develop the next generation of patient safety measures. Finally, some members expressed concern with the overlap between the efficiency measures used in the program and noted that this overlap could result in a hospital being rewarded or penalized multiple times for the same episode.

## Hospital Readmissions Reduction Program (HRRP)

The Hospital Readmissions Reduction Program is a value-based purchasing program that aims to reduce readmission to acute care hospitals paid under the IPPS. Diagnosis-related group (DRG) payment rates are reduced based on a hospital's ratio of actual to expected readmissions.

There were no measures under consideration for the HRRP in the 2016-2017 pre-rulemaking deliberations. However, MAP reviewed the current measure set and recommended that CMS consider ASPE's recommendations to mitigate the impact of the HRRP on safety net hospitals.

## Hospital-Acquired Condition Reduction Program (HACRP)

The Hospital-Acquired Condition Reduction Program (HACRP) is a value-based purchasing and public reporting program that provides an incentive to reduce the incidence of hospitalacquired conditions (HACs) to improve patient outcomes and the cost of care. HAC scores are reported on the Hospital Compare website, and the hospitals with the highest rates of HACs will have their Medicare payments reduced by 1 percent.

There were no measures under consideration for the HACRP in the 2016-2017 pre-rulemaking deliberations. However, MAP reviewed the current measure set and reiterated concerns about PSI-90. The group recommended that CMS develop measures that could replace PSI-90 in the HACRP.

# APPENDIX A: Program Summaries

The material in this appendix was drawn from the CMS Program Specific Measure Priorities and Needs document, which was released in April 2016, as well as the CMS website.

# End-Stage Renal Disease Quality Incentive Program (ESRD QIP)

#### **Program Type**

• Pay for performance and public reporting

#### **Incentive Structure**

• As of 2012, payments to dialysis facilities are reduced if facilities do not meet or exceed the required total performance score. Payment reductions will be on a sliding scale, which could amount to a maximum of 2.0 percent per year.

#### **Program Goals**

• Improve the quality of dialysis care and produce better outcomes for beneficiaries.

#### **Measure Requirements**

- Measures for anemia management reflecting FDA labeling, as well as measures for dialysis adequacy.
- Measure(s) of patient satisfaction, to the extent feasible.
- Measures of iron management, bone mineral metabolism, and vascular access, to the extent feasible.
- Measures should be NQF-endorsed, save where due consideration is given to endorsed measures of the same specified area or medical topic.
- Must include measures considering unique treatment needs of children and young adults.

 May incorporate Medicare claims and/or CROWNWeb data; alternative data sources will be considered dependent upon available infrastructure.

# Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting (PCHQR)

#### **Program Type**

• Quality Reporting Program

#### **Incentive Structure**

 PCHQR is a voluntary quality reporting program. Data are published on Hospital Compare.

#### **Program Goals**

- Provide information about the quality of care in cancer hospitals, in particular the 11 cancer hospitals that are exempt from the inpatient prospective payment system and the Inpatient Quality Reporting program
- Encourage hospitals and clinicians to improve the quality of their care, to share information, and to learn from each other's experiences and best practices

#### **Measure Requirements**

- Measures must adhere to CMS statutory requirements.
  - Measures are required to reflect consensus among affected parties, and to the extent feasible, be endorsed by the national consensus entity with a contract under

Section 1890(a) of the Social Security Act.

- The Secretary may select a measure in an area or topic in which a feasible and practical measure has not been endorsed by the entity with a contract under Section 1890(a) of the Social Security Act, as long as endorsed measures have been given due consideration.
- Measure specifications must be publicly available.
- Measure steward will provide CMS with technical assistance and clarifications on the measure as needed.
- Promote alignment with specific program attributes and across CMS and HHS programs.
- Measure alignment should support the measurement across the patient's episode of care, demonstrated by assessment of the person's trajectory across providers and settings.
- Potential use of the measure in a program does not result in negative unintended consequences (e.g., inappropriate reduced lengths of stay, overuse or inappropriate use of care or treatment, limiting access to care).
- Measures must be fully developed and tested, preferably in the PCH environment.
- Measures must be feasible to implement across PCHs (e.g., calculation, and reporting).
- Measure addresses an important condition/ topic with a performance gap and has a strong scientific evidence base to demonstrate that the measure when implemented can lead to the desired outcomes and/or more appropriate costs.
- CMS has the resources to operationalize and maintain the measure.

# Ambulatory Surgical Center Quality Reporting (ASCQR)

#### **Program Type**

• Pay-for-reporting and public reporting

#### **Incentive Structure**

 Ambulatory surgical centers (ACSs) that treat Medicare beneficiaries and fail to report data will receive a 2.0 percent reduction in their annual payment update. The program includes ASCs operating exclusively to provide surgical services to patients not requiring hospitalization.

#### **Program Goals**

- Promote higher quality, more efficient healthcare for Medicare beneficiaries through measurement.
- Allow consumers to find and compare the quality of care given at ASCs to inform decisions on where to get care.

#### Measure requirements

- Measure must adhere to CMS statutory requirements, including specification under the Hospital IQR program and posting dates on the Hospital Compare website.
  - Measures are required to reflect consensus among affected parties, and to the extent feasible, be endorsed by the national consensus entity with a contract under Section 1890(a) of the Social Security Act, currently the National Quality Forum (NQF).
  - The Secretary may select a measure in an area or topic in which a feasible and practical measure has not been endorsed, by the entity with a contract under Section 1890(a) of the Social Security Act, as long as endorsed measures have been given due consideration.

- Measure must address a NQS priority/CMS strategy goal, with preference for measures addressing the high-priority domains for future measure consideration.
- Measure must address an important condition/ topic for which there is analytic evidence that a performance gap exists and that measure implementation can lead to improvement in desired outcomes, costs, or resource utilization.
- Measure must be field tested for the ASC clinical setting.
- Measure that is clinically useful.
- Reporting of measure limits data collection and submission burden since many ASCs are small facilities with limited staffing.
- Measure must supply sufficient case numbers for differentiation of ASC performance.
- Measure must promote alignment across HHS and CMS programs.
- Measure steward will provide CMS with technical assistance and clarifications on the measure as needed.

## Inpatient Psychiatric Facilities Quality Reporting (IPFQR)

#### Program Type

Pay-for-reporting and public reporting

#### **Incentive Structure**

 Inpatient psychiatric facilities (IPFs) that do not submit data on all required measures receive a 2.0 percent reduction in annual payment update.

#### Program Goals

• Promote higher quality, more efficient healthcare for Medicare beneficiaries through measurement.

• Allow consumers to find and compare the quality of care given at ASCs to inform decisions on where to get care.

#### **Measure Requirements**

- Measure must adhere to CMS statutory requirements.
  - Measures are required to reflect consensus among affected parties, and to the extent feasible, be endorsed by the national consensus entity with a contract under Section 1890(a) of the Social Security Act.
  - The Secretary may select a measure in an area or topic in which a feasible and practical measure has not been endorsed by the entity with a contract under Section 1890(a) of the Social Security Act, as long as endorsed measures have been given due consideration.
- Measure must address an important condition/ topic for which there is analytic evidence that a performance gap exists and that measure implementation can lead to improvement in desired outcomes, costs, or resource utilization.
- The measure assesses meaningful performance differences between facilities.
- The measure addresses an aspect of care affecting a significant proportion of IPF patients.
- Measure must be fully developed, tested, and validated in the acute inpatient setting.
- Measure must address a NQS priority/CMS strategy goal, with preference for measures addressing the high-priority domains for future measure consideration.
- Measure must promote alignment across HHS and CMS programs.
- Measure steward will provide CMS with technical assistance and clarifications on the measure as needed.

# Hospital Outpatient Quality Reporting (OQR)

#### Program Type

Pay-for-reporting and public reporting

#### **Incentive Structure**

• Hospitals that do not report data on required measures receive a 2.0 percent reduction in annual payment update.

#### **Program Goals**

- Provide consumers with quality of care information to make more informed decisions about healthcare options.
- Establish a system for collecting and providing quality data to hospitals providing outpatient services such as emergency department visits, outpatient surgery, and radiology services.

#### Measure Requirements

- Measure must adhere to CMS statutory requirements.
  - Measures are required to reflect consensus among affected parties, and to the extent feasible, be endorsed by the national consensus entity with a contract under Section 1890(a) of the Social Security Act.
  - The Secretary may select a measure in an area or topic in which a feasible and practical measure has not been endorsed by the entity with a contract under Section 1890(a) of the Social Security Act, as long as endorsed measures have been given due consideration.
- Measure must address a NQS priority/CMS strategy goal, with preference for measures addressing the high priority domains for future measure consideration.
- Measure must address an important condition/

topic for which there is analytic evidence that a performance gap exists and that measure implementation can lead to improvement in desired outcomes, costs, or resource utilization.

- Measure must be fully developed, tested, and validated in the hospital outpatient setting.
- Measure must promote alignment across HHS and CMS programs.
- Feasibility of Implementation: An evaluation of feasibility is based on factors including, but not limited to:
  - The level of burden associated with validating measure data, both for CMS and for the end user.
  - Whether the identified CMS system for data collection is prepared to accommodate the proposed measure(s) and timeline for collection.
  - The availability and practicability of measure specifications (e.g., measure specifications in the public domain).
  - The level of burden the data collection system or methodology poses for an end user.
- Measure steward will provide CMS with technical assistance and clarifications on the measure as needed.

Hospital Inpatient Quality Reporting (IQR) Program and Medicare and Medicaid EHR Incentive Program for Eligible Hospitals and (CAHs)

#### Program Type

Pay-for-reporting and public reporting

#### **Incentive Structure**

• Hospitals that do not participate or meet

program requirements receive a 25 percent reduction of the annual payment update

#### **Program Goals**

- Progress towards paying providers based on the quality, rather than the quantity of care they give patients.
- Interoperability between EHRs and CMS data collection.
- To provide consumers information about hospital quality so they can make informed choices about their care.

#### **Measure Requirements**

- Measure must adhere to CMS statutory requirements.
  - Measures are required to reflect consensus among affected parties, and to the extent feasible, be endorsed by the national consensus entity with a contract under Section 1890(a) of the Social Security Act, currently the National Quality Forum (NQF).
  - The Secretary may select a measure in an area or topic in which a feasible and practical measure has not been endorsed by the entity with a contract under Section 1890(a) of the Social Security Act, as long as endorsed measures have been given due consideration.
- Measure must be claims-based or an electronically specified clinical quality measure (eCQM).
  - A Measure Authoring Tool (MAT) number must be provided for all eCQMs, created in the HQMF format.
  - eCQMs must undergo reliability and validity testing including review of the logic and value sets by the CMS partners, including, but not limited to, MITRE and the National Library of Medicine.

- eCQMs must have successfully passed feasibility testing.
- Measure may not require reporting to a proprietary registry.
- Measure must address an important condition/ topic for which there is analytic evidence that a performance gap exists and that measure implementation can lead to improvement in desired outcomes, costs, or resource utilization.
- Measure must be fully developed, tested, and validated in the acute inpatient setting.
- Measure must address a NQS priority/CMS strategy goal, with preference for measures addressing the high-priority domains and/ or measurement gaps for future measure consideration.
- Measure must promote alignment across HHS and CMS programs.
- Measure steward will provide CMS with technical assistance and clarifications on the measure as needed.

# Hospital Value-Based Purchasing (VBP)

#### Program Type

Pay for performance

#### **Incentive Structure**

The amount withheld from reimbursements increases over time:

- FY 2016: 1.75 percent
- FY 2017 and future fiscal years: 2.0 percent

#### **Program Goals**

- Improve healthcare quality by realigning hospitals' financial incentives.
- Provide incentive payments to hospitals that meet or exceed performance standards.

#### Measure Requirements

- Measure must adhere to CMS statutory requirements, including specification under the Hospital IQR program and posting dates on the Hospital Compare website.
  - Measures are required to reflect consensus among affected parties, and to the extent feasible, be endorsed by the national consensus entity with a contract under Section 1890(a) of the Social Security Act, currently the National Quality Forum (NQF).
  - The Secretary may select a measure in an area or topic in which a feasible and practical measure has not been endorsed by the entity with a contract under Section 1890(a) of the Social Security Act, as long as endorsed measures have been given due consideration.
- Measure may not require reporting to a proprietary registry.
- Measure must address an important condition/ topic for which there is analytic evidence that a performance gap exists and that measure implementation can lead to improvement in desired outcomes, costs, or resource utilization.
- Measure must be fully developed, tested, and validated in the acute inpatient setting.
- Measure must address a NQS priority/CMS strategy goal, with preference for measures addressing the high-priority domains and/ or measurement gaps for future measure consideration.
- Measure must promote alignment across HHS and CMS programs.
- Measure steward will provide CMS with technical assistance and clarifications on the measure as needed.

### Hospital Readmissions Reduction Program (HRRP)

#### **Program Type**

 Pay for performance and public reporting.
HRRP measure results are publicly reported annually on the Hospital Compare website.

#### **Incentive Structure**

 Diagnosis-related group (DRG) payment rates will be reduced based on a hospital's ratio of predicted to expected readmissions. The maximum payment reduction is 3 percent.

#### **Program Goals**

- Reduce excess readmissions in acute care hospitals paid under the Inpatient Prospective Payment System (IPPS), which includes more than three-quarters of all hospitals.
- Provide consumers with information to help them make informed decisions about their healthcare.

#### Measure Requirements

- CMS is statutorily required to select measures for applicable conditions, which are defined as conditions or procedures selected by the Secretary in which readmissions are high volume or high expenditure.
- Measures selected must be endorsed by the consensus-based entity with a contract under Section 1890 of the Act. However, the Secretary can select measures which are feasible and practical in a specified area or medical topic determined to be appropriate by the Secretary, that have not been endorsed by the entity with a contract under Section 1890 of the Act, as long as endorsed measures have been given due consideration.
- Measure methodology must be consistent with other readmissions measures currently

implemented or proposed in the HRRP.

• Measure steward will provide CMS with technical assistance and clarifications on the measure as needed.

# Hospital Acquired Condition Reduction Program (HACRP)

#### **Program Type**

• Pay-for-reporting and public reporting

#### **Incentive Structure**

• The 25 percent of hospitals that have the highest rates of HACs (as determined by the measures in the program) will have their Medicare payments reduced by 1 percent.

#### **Program Goals**

- Provide an incentive to reduce the incidence of HACs to improve both patient outcomes and the cost of care.
- Drive improvement for the care of Medicare beneficiaries, but also privately insured and Medicaid patients, through spill over benefits of improved care processes within hospitals.

#### **Measure Requirements**

- Measures must be identified as a HAC under Section 1886(d)(4)(D) or be a condition identified by the Secretary.
- Measures must address high-cost or high-volume conditions.
- Measures must be easily preventable by using evidence-based guidelines.
- Measures must not require additional system infrastructure for date submission and collection.
- Measures must be risk-adjusted.
- Measure steward will provide CMS with technical assistance and clarifications on the measure as needed.

# APPENDIX B: MAP Hospital Workgroup Roster and NQF Staff

#### WORKGROUP CHAIRS (VOTING)

Christie Upshaw Travis, MSHHA (Co-Chair)

Ronald S. Walters, MD, MBA, MHA, MS (Co-Chair)

#### ORGANIZATIONAL MEMBERS (VOTING)

America's Essential Hospitals David Engler, PhD

American Hospital Association Nancy Foster

Baylor Scott & White Health (BSWH) Marisa Valdes, RN, MSN

Blue Cross Blue Shield of Massachusetts Wei Ying, MD, MS, MBA

Children's Hospital Association Andrea Benin, MD

Kidney Care Partners Allen Nissenson, MD

Geisinger Health Systems Heather Lewis, RN

Medtronic-Minimally Invasive Therapy Group Karen Shehade, MBA

Mothers against Medical Error Jennifer Eames Huff, MPH

National Association of Psychiatric Health Systems (NAPHS) Frank Ghinassi, PhD, ABPP

National Rural Health Association Brock Slabach, MPH, FACHE

Nursing Alliance for Quality Care Kimberly Glassman, PhD, RN, NEA-BC, FAAN

Pharmacy Quality Alliance Woody Eisenberg, MD

Premier, Inc. Mimi Huizinga, MD

Project Patient Care Martin Hatlie, JD

Service Employees International Union Sarah Nolan

The Society of Thoracic Surgeons Jeff Jacobs, MD

University of Michigan Marsha Manning

# INDIVIDUAL SUBJECT MATTER EXPERTS (VOTING)

Gregory Alexander, PhD, RN, FAAN

**Elizabeth Evans, DNP** 

Lee Fleisher, MD

**Jack Jordan** 

R. Sean Morrison, MD

Ann Marie Sullivan, MD

Lindsey Wisham, BA, MPA

# FEDERAL GOVERNMENT LIAISONS (NON-VOTING)

Agency for Healthcare Research and Quality (AHRQ) Pamela Owens, PhD

Centers for Disease Control and Prevention (CDC) Daniel Pollock, MD

Centers for Medicare & Medicaid Services (CMS) Pierre Yong, MD, MPH

DUAL ELIGIBLE BENEFICIARIES WORKGROUP LIAISON (NON-VOTING)

New Jersey Hospital Association Aline Holmes

#### NATIONAL QUALITY FORUM STAFF

Helen Burstin, MD, MPH Chief Scientific Officer

Marcia Wilson, PhD, MBA Senior Vice Present, Quality Measurement

Elisa Munthali, MPH Vice President, Quality Measurement

Melissa Mariñelarena, RN, MPA Senior Director

Kate McQueston, MPH Project Manager

Desmirra Quinnonez Project Analyst

# APPENDIX C: MAP Comments on Final Measures

#### TABLE C1. ESRD QIP CURRENT MEASURE COMMENTS

| NQF # | Measure Title  | NQF Status                | National Rates | Comments  |
|-------|--|---------------------------|----------------|---|
| 1460  | National Healthcare<br>Safety Network (NHSN)<br>Bloodstream Infection in<br>Hemodialysis Patients  | Endorsed                  |                | MAP stressed that blood stream<br>infections are a critical issue for dialysis<br>patients. Overall, MAP did not support<br>the removal of this measure but MAP<br>members raised concerns that facilities<br>that perform blood cultures more<br>frequently may have higher rates on this<br>measure. MAP suggested at a threshold<br>for testing to ensure facilities are<br>performing blood cultures appropriately. |
| 2979  | Anemia of chronic kidney<br>disease: Dialysis facility<br>standardized transfusion<br>ratio (STrR) | Currently<br>under review |                |   |
| 0257  | Vascular Access Type: AV<br>Fistula  | Endorsed                  | 66%            |   |
| 0256  | Vascular Access Type -<br>Catheter >= 90 Days  | Endorsed                  | 11%            |   |
| 1454  | Proportion of Patients with<br>Hypercalcemia   | Endorsed                  | 1%             | MAP members noted the small<br>performance gap for this measure. MAP<br>recognized the legislative requirement<br>for a bone and mineral metabolism<br>measure but raised concerns about the<br>clinical impact of this measure.  |
| 2496  | Standardized Readmission<br>Ratio (SRR) for dialysis<br>facilities                                 | Endorsed                  |                |   |
| 0369  | Standardized<br>Hospitalization Ratio for<br>Dialysis Facilities                                   | Endorsed                  |                |   |
| 1463  | Standardized Mortality<br>Ratio for Dialysis Facilities  | Endorsed                  |                |   |
|       | Kt/V Dialysis Adequacy<br>Comprehensive Clinical<br>Measure  |                           |                |   |
| 0249  | Adult Hemodialysis<br>Adequacy   | Endorsed                  | 93%            | MAP members raised concerns that this measure may be topped out.  |

| NQF # | Measure Title  | NQF Status   | National Rates | Comments  |
|-------|--|--------------|----------------|---|
| 0318  | Adult Peritoneal Dialysis<br>Adequacy                                      | Endorsed     | 84%            |   |
| 1423  | Pediatric Hemodialysis<br>Adequacy   | Endorsed     | 89%            |   |
| N/A   | Pediatric Peritoneal<br>Dialysis Adequacy                                  | Not Endorsed | 56%            |   |
| 0258  | CAHPS In-Center<br>Hemodialysis Survey                                     | Endorsed     |                |   |
| N/A   | Mineral Metabolism<br>Reporting Measure                                    | Not Endorsed |                |   |
| N/A   | Anemia Management<br>Reporting Measure                                     | Not Endorsed |                |   |
| 0431  | NHSN Healthcare<br>Personnel Influenza<br>Vaccination Reporting<br>Measure | Endorsed     |                |   |
| 0418  | Clinical Depression<br>Screening and Follow-Up<br>Reporting Measure        | Endorsed     |                | MAP recommended that CMS move to<br>a patient-reported outcome measure to<br>assess depression. |
| 0420  | Pain Assessment and<br>Follow-up Reporting<br>Measure                      | Endorsed     |                | MAP recommended that CMS move to<br>a patient-reported outcome measure to<br>assess pain.       |

#### TABLE C2. PCHQR CURRENT MEASURE COMMENTS

| NQF # | Measure Title  | NQF Status                    | National Rates | Comments  |
|-------|--|-------------------------------|----------------|---|
| 0166  | HCAHPS - Hospital<br>Consumer Assessment of<br>Healthcare Providers and<br>Systems Survey  | Endorsed                      |                |   |
| 0138  | National Healthcare Safety<br>Network (NHSN) Catheter-<br>Associated Urinary Tract<br>Infection(CAUTI) Outcome<br>Measure  | Endorsed                      |                |   |
| 0139  | National Healthcare<br>Safety Network (NHSN)<br>Central line-associated<br>Bloodstream Infection<br>(CLABSI) Outcome<br>Measure  | Endorsed                      |                |   |
| 0753  | American College of<br>Surgeons - Centers for<br>Disease Control and<br>Prevention (ACS-CDC)<br>Harmonized Procedure<br>Specific Surgical Site<br>Infection (SSI) Outcome<br>Measure | Endorsed                      |                |   |
| 1717  | National Healthcare Safety<br>Network (NHSN) Facility-<br>wide Inpatient Hospital-<br>onset Clostridium difficile<br>Infection (CDI) Outcome<br>Measure                              | Endorsed                      |                |   |
| 1716  | National Healthcare<br>Safety Network (NHSN)<br>Facility-Wide Inpatient<br>Hospital-onset Methicillin-<br>resistant Staphylococcus<br>aureus (MRSA) Bacteremia<br>Outcome Measure    | Endorsed                      |                |   |
| 2936  | Admissions and Emergency<br>Department (ED) Visits<br>for Patients Receiving<br>Outpatient Chemotherapy  | Failed Initial<br>Endorsement |                | MAP recommended that this measure<br>be removed from the program as it<br>failed NQF endorsement. |
| 0384  | Oncology: Medical and<br>Radiation - Pain Intensity<br>Quantified  | Endorsed                      |                |   |
| 0383  | Oncology: Plan of Care for<br>Pain – Medical Oncology<br>and Radiation Oncology  | Endorsed                      |                |   |

| NQF # | Measure Title  | NQF Status | National Rates | Comments   |
|-------|--|------------|----------------|--|
| 0382  | Oncology: Radiation Dose<br>Limits to Normal Tissues   | Endorsed   |                |  |
| 0559  | Combination<br>chemotherapy is<br>considered or administered<br>within 4 months (120 days)<br>of diagnosis for women<br>under 70 with AJCC<br>T1cNOMO, or Stage IB - III<br>hormone receptor negative<br>breast cancer | Endorsed   | 94%            | MAP noted universally high performance<br>on this measure and recommended that<br>it could be removed in the future. |
| 0220  | Adjuvant Hormonal<br>Therapy   | Endorsed   | 97%            | MAP noted universally high performance<br>on this measure and recommended that<br>it could be removed in the future. |
| 0390  | Prostate Cancer: Adjuvant<br>Hormonal Therapy for<br>High Risk Prostate Cancer<br>Patients   | Endorsed   |                |  |
| 0389  | Prostate Cancer: Avoidance<br>of Overuse of Bone Scan<br>for Staging Low Risk<br>Prostate Cancer Patients  | Endorsed   |                |  |
| 0223  | Adjuvant Chemotherapy<br>is Considered or<br>Administered Within 4<br>Months (120 days) of<br>Diagnosis to Patients Under<br>the Age of 80 with AJCC<br>III (lymph node positive)<br>Colon Cancer                      | Endorsed   | 94%            | MAP noted universally high performance<br>on this measure and recommended that<br>it could be removed in the future. |
| 1822  | External Beam<br>Radiotherapy for Bone<br>Metastases   | Endorsed   |                |  |
| 0431  | Influenza Vaccination<br>Coverage among<br>Healthcare Personnel  | Endorsed   |                |  |

#### TABLE C3. ASCQ CURRENT MEASURE COMMENTS

| NQF # | Measure Title  | NQF Status                           | National Rate<br>2014 | National Rate<br>2013 | Comments  |
|-------|--|--------------------------------------|-----------------------|-----------------------|---|
| 0263  | Patient Burn   | Endorsement<br>Removed               | 0.364                 | 0.247                 |   |
| 0267  | Wrong Site, Wrong Side,<br>Wrong Patient, Wrong<br>Procedure, Wrong Implant  | Endorsement<br>Removed               | 0.028                 | 0.039                 |   |
| 0266  | Patient Fall   | Endorsed                             | 0.095                 | 0.156                 |   |
| 0264  | Prophylactic Intravenous<br>(IV) Antibiotic Timing   | Failed<br>Maintenance<br>Endorsement | 960.04                | 962.43                | MAP recommended<br>that this measure be<br>removed from the<br>program as it failed<br>NQF endorsement. |
| N/A   | Normothermia Outcome:<br>Percentage of patients<br>having surgical procedures<br>under general or neuraxial<br>anesthesia of 60 minutes<br>or more in duration who<br>are normothermic within<br>15 minutes of arrival in the<br>post-anesthesia care unit<br>(PACU) | Never<br>Submitted                   |                       |                       |   |
| 9999  | Safe Surgery Checklist Use   | Not Endorsed                         | 99.75                 |                       | MAP recommended<br>that this measure be<br>removed given the<br>lack of variation in<br>performance.    |
| 9999  | ASC Facility Volume Data<br>on Selected ASC Surgical<br>Procedures   | Not Endorsed                         | 3978                  |                       |   |
| 0265  | All-Cause Hospital<br>Transfer/ Admission  | Endorsed                             | 0.475                 | 0.537                 |   |
| 1536  | Cataracts: Improvement in<br>Patient's Visual Function<br>within 90 Days Following<br>Cataract Surgery   | Endorsed                             |                       |                       |   |
| 0431  | Influenza Vaccination<br>Coverage Among<br>Healthcare Personnel  | Endorsed                             | 74.62                 |                       |   |
| 0658  | Appropriate Follow-<br>Up Interval for Normal<br>Colonoscopy in Average<br>Risk Patients   | Endorsed                             | 78.38                 |                       |   |

| NQF # | Measure Title  | NQF Status         | National Rate<br>2014 | National Rate<br>2013 | Comments |
|-------|--|--------------------|-----------------------|-----------------------|----------|
| 0659  | Endoscopy/Polyp<br>Surveillance: Colonoscopy<br>Interval for Patients with<br>a History of Adenomatous<br>Polyps - Avoidance of<br>Inappropriate Use | Endorsed           | 80.38                 |                       |          |
| 2539  | Facility 7-Day Risk-<br>Standardized Hospital<br>Visit Rate after Outpatient<br>Colonoscopy  | Endorsed           |                       |                       |          |
| N/A   | Unplanned Anterior<br>Vitrectomy   | Never<br>Submitted |                       |                       |          |
| N/A   | OAS CAHPS (five measures)  | Never<br>Submitted |                       |                       |          |

#### TABLE C4. IPFQR CURRENT MEASURE COMMENTS

| NQF # | Measure Title  | NQF Status      | National Rate | Comments  |
|-------|--|-----------------|---------------|---|
| 1661  | SUB-1 Alcohol Use<br>Screening   | Endorsed        | 71.01         | MAP noted the importance of<br>addressing substance abuse but<br>recommended that CMS prioritize<br>measures that will better address<br>the quality of mental health care. |
| 1651  | TOB-1 Tobacco Use<br>Screening   | Endorsed        |               | MAP noted the importance<br>of tobacco cessation but<br>recommended that CMS prioritize<br>measures that will better address<br>the quality of mental health care.          |
| N/A   | Screening for Metabolic<br>Disorders   | Never Submitted |               |   |
| 0640  | Hours of Physical<br>Restraint   | Endorsed        | 0.41          |   |
| 0641  | Hours of Seclusion Use   | Endorsed        | 0.21          |   |
| 1654  | TOB-2 Tobacco Use<br>Treatment Provided or<br>Offered and the subset<br>measure TOB-2a Tobacco<br>Use Treatment  | Endorsed        |               | MAP noted the importance<br>of tobacco cessation but<br>recommended that CMS prioritize<br>measures that will better address<br>the quality of mental health care.          |
| 1663  | SUB-2 Alcohol Use Brief<br>Intervention Provided<br>or Offered and SUB-<br>2a Alcohol Use Brief<br>Intervention  | Endorsed        |               | MAP noted the importance of<br>addressing substance abuse but<br>recommended that CMS prioritize<br>measures that will better address<br>the quality of mental health care. |
| 1659  | Influenza Immunization   | Endorsed        | 94%           |   |
| 1656  | TOB-3 Tobacco Use<br>Treatment Provided or<br>Offered at Discharge<br>and the subset measure<br>TOB-3a Tobacco Use<br>Treatment at Discharge                             | Endorsed        |               | MAP noted the importance<br>of tobacco cessation but<br>recommended that CMS prioritize<br>measures that will better address<br>the quality of mental health care.          |
| 1664  | SUB-3 Alcohol & Other<br>Drug Use Disorder<br>Treatment Provided or<br>Offered at Discharge<br>and SUB-3a Alcohol &<br>Other Drug Use Disorder<br>Treatment at Discharge | Endorsed        |               | MAP noted the importance of<br>addressing substance abuse but<br>recommended that CMS prioritize<br>measures that will better address<br>the quality of mental health care. |
| 0560  | Patients Discharged on<br>Multiple Antipsychotic<br>Medications with<br>Appropriate Justification  | Endorsed        | 36.62         |   |

| NQF # | Measure Title   | NQF Status             | National Rate | Comments  |
|-------|---|------------------------|---------------|---|
| 0647  | Transition Record with<br>Specified Elements<br>Received by Discharged<br>Patients (Discharges from<br>an Inpatient Facility to<br>Home/Self Care or Any<br>Other Site of Care) | Endorsed               |               |   |
| 0648  | Timely Transmission of<br>Transition Record   | Endorsed               |               |   |
| 0576  | Follow-Up After<br>Hospitalization for Mental<br>Illness (FUH)  | Endorsed               | Not Available | MAP recommended that this<br>measure be re-specified for acute<br>care and submitted for NQF<br>endorsement.  |
| 0431  | Influenza Vaccination<br>Coverage Among<br>Healthcare Personnel   | Endorsed               |               |   |
| N/A   | Use of Electronic Health<br>Record  | Never Submitted        |               |   |
| N/A   | Assessment of Patient<br>Experience of Care   | Never Submitted        |               |   |
| 2860  | 30-Day All-Cause<br>Unplanned Readmission<br>Following Psychiatric<br>Hospitalization in an IPF   | Endorsed               |               |   |
| 0557  | Post Discharge<br>Continuing Care Plan<br>Created   | Endorsement<br>Removed |               | MAP noted that this measure<br>has been removed from IPFQR<br>Program for FY 2018 Payment<br>Determination & Subsequent<br>Years. MAP recommends the<br>removal of measures that have<br>had NQF endorsement removed. |
| 0558  | Post Discharge<br>Continuing Care Plan<br>Transmitted to Next Level<br>of Care at Discharge   | Endorsement<br>Removed |               | MAP noted that this measure<br>has been removed from IPFQR<br>Program for FY 2018 Payment<br>Determination & Subsequent<br>Years. MAP recommends the<br>removal of measures that have<br>had NQF endorsement removed. |

#### TABLE C5. HOQR CURRENT MEASURE COMMENTS

| NQF # | Measure Title   | NQF Status                           | National Rate | Comments   |
|-------|---|--------------------------------------|---------------|--|
| 0498  | Door to Diagnostic Evaluation<br>by a Qualified Medical<br>Professional   | Failed<br>Maintenance<br>Endorsement | 25 Minutes    | MAP recommended the removal<br>of measures that have failed<br>maintenance endorsement.  |
| 0662  | Median Time to Pain<br>Management for Long Bone<br>Fracture   | Failed<br>Maintenance<br>Endorsement | 52 Minutes    | MAP recommended the removal<br>of measures that have failed<br>maintenance endorsement.  |
| 0496  | Median time from ED Arrival to<br>ED Departure for Discharged<br>ED Patients  | Endorsed                             | 148 Minutes   | MAP noted the potential burden<br>in collecting this measure and<br>recommended that it could<br>be removed to allow for the<br>implementation of a higher value<br>measure. |
| 0499  | Left Without Being Seen   | Failed<br>Maintenance<br>Endorsement | 2%            | MAP recommended the removal of measures that have failed maintenance endorsement.  |
| 0289  | Median Time to ECG  | Failed<br>Maintenance<br>Endorsement | 7 Minutes     | MAP recommended the removal of measures that have failed maintenance endorsement.  |
| 0287  | Median Time to Fibrinolysis   | Failed<br>Maintenance<br>Endorsement | 56%           | MAP recommended the removal<br>of measures that have failed<br>maintenance endorsement.  |
| 0288  | Fibrinolytic Therapy Received<br>Within 30 Minutes of ED Arrival  | Failed<br>Maintenance<br>Endorsement | 58%           | MAP recommended the removal of measures that have failed maintenance endorsement.  |
| 0290  | Median Time to Transfer to<br>Another Facility for Acute<br>Coronary Intervention   | Endorsed                             | 57 Minutes    |  |
| 0286  | Aspirin at Arrival  | Failed<br>Maintenance<br>Endorsement | 0.96          | MAP recommended the removal<br>of measures that have failed<br>maintenance endorsement.  |
| 0661  | ED- Head CT or MRI Scan<br>Results for Acute Ischemic<br>Stroke or Hemorrhagic Stroke<br>who Received Head CT or MRI<br>Scan Interpretation Within 45<br>Minutes of Arrival | Endorsed                             | 0.68          |  |
| 9999  | Mammography Follow-Up<br>Rates  | Failed Initial<br>Endorsement        | 8.9%          | MAP recommended the removal<br>of measures that failed NQF<br>endorsement.   |
| 0513  | Thorax CT- Use of Contrast<br>Material  | Endorsed                             | 2.1%          |  |
| 9999  | Abdomen CT - Use of Contrast<br>Material  | Failed Initial<br>Endorsement        | 8.4%          | MAP recommended the removal<br>of measures that failed NQF<br>endorsement.   |

| NQF # | Measure Title   | NQF Status                    | National Rate | Comments  |
|-------|---|-------------------------------|---------------|---|
| 9999  | Simultaneous Use of Brain<br>Computed Tomography<br>(CT) and Sinus Computed<br>Tomography (CT)  | Failed Initial<br>Endorsement | 2.9%          | MAP recommended the removal<br>of measures that failed NQF<br>endorsement.  |
| 0669  | Cardiac Imaging for<br>Preoperative Risk Assessment<br>for Non-Cardiac Low-Risk<br>Surgery  | Endorsed                      | 4.8%          |   |
| 0514  | MRI Lumbar Spine for Low<br>Back Pain   | Endorsed                      | 39.5%         |   |
| 1822  | External Beam Radiotherapy<br>for Bone Metastases   | Endorsed                      |               |   |
| 0658  | Appropriate Follow-Up Interval<br>for Normal Colonoscopy in<br>Average Risk Patients  | Endorsed                      | 74%           |   |
| 0659  | Endoscopy/Polyp Surveillance:<br>Colonoscopy Interval for<br>Patients with a History of<br>Adenomatous Polyps -<br>Avoidance of Inappropriate Use | Endorsed                      | 80%           |   |
| 2539  | Facility 7-Day Risk-<br>Standardized Hospital<br>Visit Rate after Outpatient<br>Colonoscopy   | Endorsed                      |               |   |
| 9999  | Safe Surgery Checklist Use  | Not Endorsed                  |               | MAP noted that this measure is<br>not endorsed and that measures<br>should be submitted for NQF<br>endorsement. MAP also noted the<br>uniformly high performance and<br>questioned if there was still an<br>opportunity for improvement on<br>this measure. |
| 9999  | Hospital Outpatient<br>Department Volume on<br>Selected Outpatient Surgical<br>Procedures   | Not Endorsed                  |               | MAP noted that this measure is<br>not endorsed and that measures<br>should be submitted for NQF<br>endorsement. MAP also noted<br>that the procedures included in<br>this measure may not be highly<br>sensitive to volume.                                 |
| 1536  | Cataracts: Improvement in<br>Patient's Visual Function within<br>90 Days Following Cataract<br>Surgery  | Endorsed                      |               |   |

| NQF # | Measure Title   | NQF Status                           | National Rate | Comments   |
|-------|---|--------------------------------------|---------------|--|
| 0489  | The Ability for Providers with<br>HIT to Receive Laboratory Data<br>Electronically Directly into their<br>ONC-Certified EHR System<br>as Discrete Searchable Data<br>Elements | Failed<br>Maintenance<br>Endorsement |               | MAP recommended the removal<br>of measures that have failed<br>maintenance endorsement.              |
| 9999  | Tracking Clinical Results<br>between Visits   | Not Endorsed                         |               | MAP recommended that this measure be submitted for NQF endorsement.                                  |
| 0431  | Influenza Vaccination Coverage<br>among Healthcare Personnel  | Endorsed                             |               |  |
| 2936  | Admissions and Emergency<br>Department (ED) Visits for<br>Patients Receiving Outpatient<br>Chemotherapy   | Failed Initial<br>Endorsement        |               | MAP recommended that this<br>measure be removed from<br>the program as it failed NQF<br>endorsement. |
| 2687  | Hospital Visits after Hospital<br>Outpatient Surgery  | Endorsed                             |               |  |
| N/A   | OAS CAHPS (five measures)   | Never Submitted                      |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement.                            |

#### TABLE C6. IQR CURRENT MEASURE COMMENTS

| NQF # | Measure Title  | NQF Status         | National Rate | Comments  |
|-------|--|--------------------|---------------|---|
| 0138  | NHSN Catheter-Associated Urinary<br>Tract Infection (CAUTI) Outcome<br>Measure   | Endorsed           | N/A           |   |
| 1717  | NHSN Facility-wide Inpatient<br>Hospital-onset Clostridium difficile<br>Infection (CDI) Outcome Measure  | Endorsed           | N/A           |   |
| 0139  | NHSN Central line-associated<br>Bloodstream Infection (CLABSI)<br>Outcome Measure  | Endorsed           | N/A           |   |
| 0753  | ACS-CDC Harmonized Procedure<br>Specific Surgical Site Infection<br>(SSI) Outcome Measure  | Endorsed           | N/A           |   |
| 1716  | NHSN Facility-Wide Inpatient<br>Hospital-onset Methicillin-resistant<br>Staphylococcus aureus (MRSA)<br>Bacteremia Outcome Measure                                     | Endorsed           | N/A           |   |
| 0431  | Influenza Vaccination Coverage<br>Among Healthcare Personnel   | Endorsed           | 86%           |   |
| 2431  | Hospital-level, Risk-Standardized<br>Payment Associated with a<br>30-Day Episode-of-Care for Acute<br>Myocardial Infarction (AMI)                                      | Endorsed           | \$22,760      |   |
| 2436  | Hospital-level, Risk-Standardized<br>Payment Associated with a 30-Day<br>Episode-of-Care for Heart Failure<br>(HF)   | Endorsed           | \$15,959      |   |
| 2579  | Hospital-level, Risk-Standardized<br>Payment Associated with a 30-Day<br>Episode-of-Care for Pneumonia   | Endorsed           | \$14,817      |   |
| 2158  | Payment-Standardized Medicare<br>Spending Per Beneficiary (MSPB)   | Endorsed           |               |   |
| N/A   | Hospital-Level, Risk-Standardized<br>Payment Associated with a 90-Day<br>Episode-of-Care for Elective<br>Primary Total Hip and/or Total<br>Knee Arthroplasty (THA/TKA) | Never<br>Submitted |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement. |
| N/A   | Cellulitis Clinical Episode-Based<br>Payment Measure   | Never<br>Submitted |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement. |
| N/A   | Gastrointestinal (GI) Hemorrhage<br>Clinical Episode-Based Payment<br>Measure  | Never<br>Submitted |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement. |
| N/A   | Kidney/Urinary Tract Infection<br>Clinical Episode-Based Payment<br>Measure  | Never<br>Submitted |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement. |

| NQF # | Measure Title   | NQF Status         | National Rate | Comments  |
|-------|---|--------------------|---------------|---|
| N/A   | Aortic Aneurysm Procedure clinical<br>episode-based payment (AA<br>Payment) Measure   | Never<br>Submitted |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement. |
| N/A   | Cholecystectomy and Common<br>Duct Exploration Clinical Episode-<br>Based Payment Measure   | Never<br>Submitted |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement. |
| N/A   | Spinal Fusion Clinical Episode-<br>Based Payment Measure  | Never<br>Submitted |               | MAP recommended that this measure be submitted for NQF endorsement.       |
| 0230  | Hospital 30-day, All-Cause,<br>Risk-Standardized Mortality<br>Rate (RSMR) Following Acute<br>Myocardial Infarction (AMI)<br>Hospitalization                     | Endorsed           | 14.1%         |   |
| 2558  | Hospital 30-Day, All-Cause,<br>Risk-Standardized Mortality Rate<br>(RSMR) Following Coronary Artery<br>Bypass Graft (CABG) surgery                              | Endorsed           | 3.2%          |   |
| 1839  | Hospital 30-Day, All-Cause,<br>Risk-Standardized Mortality<br>Rate (RSMR) Following Chronic<br>Obstructive Pulmonary Disease<br>(COPD) Hospitalization          | Endorsed           | 8.0%          |   |
| 0229  | Hospital 30-Day, All-Cause,<br>Risk-Standardized Mortality Rate<br>(RSMR) Following Heart Failure<br>(HF) hospitalization.                                      | Endorsed           | 12.1%         |   |
| 0468  | Hospital 30-Day, All-Cause,<br>Risk-Standardized Mortality Rate<br>(RSMR) Following Pneumonia<br>Hospitalization  | Endorsed           | 16.3%         |   |
| 0505  | Hospital 30-Day All-Cause,<br>Risk-Standardized Readmission<br>Rate (RSRR) Following Acute<br>Myocardial Infarction (AMI)<br>Hospitalization                    | Endorsed           | 16.8%         |   |
| 2515  | Hospital 30-Day, All-Cause,<br>Unplanned, Risk-Standardized<br>Readmission Rate (RSRR)<br>Following Coronary Artery Bypass<br>Graft (CABG) Surgery              | Endorsed           | 14.4%         |   |
| 1891  | Hospital-Level, 30-Day, All-Cause,<br>Risk-Standardized Readmission<br>Rate (RSRR) Following Chronic<br>Obstructive Pulmonary Disease<br>(COPD) Hospitalization | Endorsed           | 20.0%         |   |

| NQF # | Measure Title   | NQF Status                             | National Rate                             | Comments  |
|-------|---|--|---|---|
| 0330  | Hospital 30-Day, All-Cause, Risk-<br>Standardized Readmission Rate<br>(RSRR) Following Heart Failure<br>(HF) Hospitalization.   | Endorsed                               | 21.9%                                     |   |
| 1789  | Hospital-Wide All-Cause,<br>Unplanned Readmission Measure<br>(HWR)  | Endorsed                               | 15.6%                                     |   |
| 0506  | Hospital 30-Day, All-Cause, Risk-<br>Standardized Readmission Rate<br>(RSRR) Following Pneumonia<br>Hospitalization.  | Endorsed                               | 17.1%                                     |   |
| N/A   | 30-Day Risk-Standardized<br>Readmission Rate Following Stroke<br>Hospitalization  | Withdrawn                              | 12.5%                                     | MAP recommended that this<br>measure be submitted for NQF<br>endorsement. |
| 1551  | Hospital-level 30 day, all-cause,<br>risk-standardized readmission rate<br>(RSRR) following elective primary<br>total hip arthroplasty (THA) and/or<br>total knee arthroplasty (TKA)  | Endorsed                               | 4.6%                                      |   |
| 2881  | Excess Days in Acute Care<br>after Hospitalization for Acute<br>Myocardial Infarction   | Currently<br>under review              |   |   |
| 2880  | Excess Days in Acute Care after<br>Hospitalization for Heart Failure  | Currently<br>under review              |   |   |
| 2882  | Excess Days in Acute Care after<br>Hospitalization for Pneumonia  | Currently<br>under review              |   |   |
| 1550  | Hospital-level risk-standardized<br>complication rate (RSCR)<br>following elective primary total hip<br>arthroplasty (THA) and/or total<br>knee arthroplasty (TKA).   | Endorsed                               | 3.0%                                      |   |
| 0351  | Death among Surgical Inpatients<br>with Serious, Treatable<br>Complications   | Endorsed                               | 136.48 per<br>1,000 patient<br>discharges |   |
| 0531  | Patient Safety for Selected<br>Indicators, PSI 90 (latrogenic<br>pneumothorax, perioperative PE or<br>DVT, post-op wound dehiscence,<br>accidental puncture or laceration,<br>pressure ulcers, central venous<br>catheter-related blood stream<br>infection, post-op hip fracture,<br>post-op sepsis) | See updated<br>specifications<br>below | 0.90                                      |   |

| NQF # | Measure Title  | NQF Status                           | National Rate | Comments   |
|-------|--|--------------------------------------|---------------|--|
| 0531  | Patient Safety for Selected<br>Indicators Composite Measure<br>(pressure ulcers, iatrogenic<br>pneumothorax rate, post-op hip<br>fracture rate, post-op hemorrhage<br>or hematoma, physiologic and<br>metabolic derangement, post-op<br>respiratory failure, post-op PE<br>or DVT, post-op sepsis, post-op<br>wound dehiscence, and accidental<br>puncture or laceration rate),<br>Modified PSI 90 (Updated Title:<br>Patient Safety and Adverse Events<br>Composite) - Finalized for FY<br>2019 Payment Determination and<br>Subsequent Years | Endorsed                             | N/A           |  |
| 0495  | Median Time from ED Arrival to<br>ED Departure for Admitted ED<br>Patients   | Endorsed                             |               |  |
| 0497  | Admit Decision Time to ED<br>Departure Time for Admitted<br>Patients   | Endorsed                             | 280 Minutes   |  |
| 1659  | Influenza immunization   | Currently<br>under review            | 94%           |  |
| 0469  | Elective Delivery  | Endorsed                             | 3%            |  |
| 0500  | Severe Sepsis and Septic Shock:<br>Management Bundle (Composite<br>Measure)  | Endorsed                             |               |  |
| 0376  | Incidence of Potentially<br>Preventable Venous<br>Thromboembolism  | Failed<br>Maintenance<br>Endorsement |               | MAP recommended that measures<br>that failed NQF endorsement be<br>removed from the program. |
| N/A   | Median Time from ED Arrival to<br>ED Departure for Admitted ED<br>Patients*  | Never<br>Submitted                   |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement.                    |
| N/A   | Admit Decision Time to ED<br>Departure Time for Admitted<br>Patients   | Never<br>Submitted                   |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement.                    |
| N/A   | Primary PCI Received within 90<br>minutes of hospital arrival  | Never<br>Submitted                   |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement.                    |
| N/A   | Home Management Plan of Care<br>Document Given to Patient/<br>Caregiver  | Never<br>Submitted                   |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement.                    |
| 3058  | Hearing screening before hospital discharge  | Endorsed                             |               |  |
| 2829  | Elective Delivery  | Endorsed                             |               |  |

| NQF # | Measure Title  | NQF Status                    | National Rate | Comments  |
|-------|--|-------------------------------|---------------|---|
| 2830  | Exclusive Breast Milk Feeding<br>and the subset measure PC-05a<br>Exclusive Breast Milk Feeding<br>Considering Mother's Choice | Endorsed                      |               |   |
| 3042  | Discharged on Antithrombotic<br>Therapy  | Failed Initial<br>Endorsement |               | MAP recommended that measures<br>that failed NQF endorsement be<br>removed from the program.  |
| 3043  | Anticoagulation Therapy for Atrial<br>Fibrillation/Flutter   | Failed Initial<br>Endorsement |               | MAP recommended that measures<br>that failed NQF endorsement be<br>removed from the program.  |
| 3045  | Antithrombotic Therapy by the<br>End of Hospital Day Two   | Failed Initial<br>Endorsement |               | MAP recommended that measures<br>that failed NQF endorsement be<br>removed from the program.  |
| 3046  | Discharged on Statin Medication  | Failed Initial<br>Endorsement |               | MAP recommended that measures<br>that failed NQF endorsement be<br>removed from the program.  |
| N/A   | Stroke Education   | Never<br>Submitted            |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement.   |
| 3047  | Assessed for Rehabilitation  | Failed Initial<br>Endorsement |               | MAP recommended that measures<br>that failed NQF endorsement be<br>removed from the program.  |
| N/A   | Venous Thromboembolism<br>Prophylaxis  | Never<br>Submitted            |               | MAP recommended that this measure be submitted for NQF endorsement.   |
| N/A   | Intensive Care Unit Venous<br>Thromboembolism Prophylaxis  | Never<br>Submitted            |               | MAP recommended that this measure be submitted for NQF endorsement  |
| 0166  | HCAHPS - Hospital Consumer<br>Assessment of Healthcare<br>Providers and Systems Survey   | Endorsed                      |               |   |
| 0228  | 3-Item Care Transitions Measure<br>(CTM-3)   | Endorsed                      |               |   |
| N/A   | Hospital Survey on Patient Safety<br>Culture   | Never<br>Submitted            |               |   |
| N/A   | Safe Surgery Checklist Use   | Never<br>Submitted            |               | MAP recommended that this<br>measure be submitted for NQF<br>endorsement. MAP cautioned<br>that performance on this measure<br>may be high and there is limited<br>opportunity for improvement. |
| 0437  | Thrombolytic Therapy   | Endorsed                      |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019.   |
| 0375  | VTE Discharge Instructions   | Endorsement<br>Removed        |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019.   |

| NQF # | Measure Title   | NQF Status | National Rate | Comments  |
|-------|---|------------|---------------|---|
| N/A   | Aspirin Prescribed at Discharge for<br>AMI  |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Fibrinolytic Therapy Received<br>Within 30 Minutes of Hospital<br>Arrival   |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Statin Prescribed at Discharge  |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Healthy Term newborn  |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Initial Antibiotic Selection for<br>Community-Acquired Pneumonia<br>(CAP) in Immunocompetent<br>Patients  |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Prophylactic Antibiotic Received<br>within 1 Hour Prior to Surgical<br>Incision   |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Prophylactic Antibiotic Selection<br>for Surgical Patients  |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Urinary Catheter Removed on<br>Postoperative Day 1 (POD1) or<br>Postoperative Day 2 (POD2) with<br>Day of Surgery Being Day Zero.                     |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Thrombolytic Therapy  |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Venous Thromboembolism<br>Patients with Anticoagulation<br>Overlap Therapy  |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Venous Thromboembolism<br>Patients Receiving Unfractionated<br>Heparin (UFH) with Dosages/<br>Platelet Count Monitoring by<br>Protocol (or Nomogram). |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Venous Thromboembolism<br>Discharge Instructions.   |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Incidence of Potentially<br>Preventable VTE   |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Participation in a Systematic<br>Clinical Database Registry for<br>Nursing Sensitive Care   |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |
| N/A   | Participation in a Systematic<br>Clinical Database Registry for<br>General Surgery  |            |               | MAP noted that this measure has<br>been finalized for removal for FY<br>2019. |

ISBN 978-1-68248-040-3 © 2017 National Quality Forum

NATIONAL QUALITY FORUM 1030 15TH STREET, NW, SUITE 800 WASHINGTON, DC 20005

www.qualityforum.org